Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer

By Larsen Finn Ole   Boisen Mogens Karsbøl   Fromm Annelene L.   Jensen Benny Vittrup  

Acta Oncologica, Vol. 51, Iss. 2, 2012-02 ,pp. : 231-233

Informa Healthcare

Access to resources Recommend Favorite

Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer

By Benavides M.   García-Alfonso P.   Cobo M.   Muñoz-Martín A.   Gil-Calle S.   Carabantes F.   Villar E.   Graupera J.   Balcells M.   Pérez-Manga G.  

Medical Oncology, Vol. 21, Iss. 3, 2004-09 ,pp. : 255-262

Humana Press, Inc

Access to resources Recommend Favorite

Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab

By Garcia-Albeniz Xabier  

Tumor Biology, Vol. 32, Iss. 2, 2011-04 ,pp. : 417-424

Springer Publishing Company

Access to resources Recommend Favorite

MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer

By Paule Bernard  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1066-1072

Humana Press, Inc

Access to resources Recommend Favorite

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

By Pfeiffer Per   Nielsen Dorte   Yilmaz Mette   Iversen Anja   Vejlø Christian   Jensen Benny Vittrup  

Acta Oncologica, Vol. 46, Iss. 5, 2007-01 ,pp. : 697-701

Informa Healthcare

Access to resources Recommend Favorite